GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 4SC AG (GREY:FSCGF) » Definitions » Capex-to-Revenue

4SC AG (4SC AG) Capex-to-Revenue : 0.00 (As of Dec. 2023)


View and export this data going back to 2008. Start your Free Trial

What is 4SC AG Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

4SC AG's Capital Expenditure for the six months ended in Dec. 2023 was $0.00 Mil. Its Revenue for the six months ended in Dec. 2023 was $0.19 Mil.

Hence, 4SC AG's Capex-to-Revenue for the six months ended in Dec. 2023 was 0.00.


4SC AG Capex-to-Revenue Historical Data

The historical data trend for 4SC AG's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

4SC AG Capex-to-Revenue Chart

4SC AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.06 0.02 - 0.01 0.01

4SC AG Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.11 - - - -

Competitive Comparison of 4SC AG's Capex-to-Revenue

For the Biotechnology subindustry, 4SC AG's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


4SC AG's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 4SC AG's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where 4SC AG's Capex-to-Revenue falls into.



4SC AG Capex-to-Revenue Calculation

4SC AG's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-0.002) / 0.332
=0.01

4SC AG's Capex-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 0.193
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


4SC AG  (GREY:FSCGF) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


4SC AG Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of 4SC AG's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


4SC AG (4SC AG) Business Description

Traded in Other Exchanges
Address
Fraunhoferstraße 22, Planegg-Martinsried, DEU, 82152
4SC AG is a clinical-stage biopharmaceutical company developing small-molecule drugs that can target key indications in cancer with high unmet medical needs. Its pipeline is protected by a comprehensive portfolio of patents and currently comprises two drug candidates in clinical development resminostat and Domatinostat. It Geographic area of the company is Germany, the EU, and Other countries, and the majority of the revenue comes from Other Countries.

4SC AG (4SC AG) Headlines

From GuruFocus

Q1 2020 4Sc AG Earnings Call Transcript

By GuruFocus Research 03-08-2024

Q2 2022 4Sc AG Earnings Call Transcript

By GuruFocus Research 03-08-2024

Q2 2019 4Sc AG Earnings Call (German) Transcript

By GuruFocus Research 03-08-2024

Q2 2020 4Sc AG Earnings Call Transcript

By GuruFocus Research 03-08-2024

Q3 2023 4Sc AG Earnings Call Transcript

By GuruFocus Research 03-08-2024

Q1 2021 4Sc AG Earnings Call Transcript

By GuruFocus Research 03-08-2024

Half Year 2021 4Sc AG Earnings Call Transcript

By GuruFocus Research 03-08-2024

Q3 2019 4Sc AG Earnings Call Transcript

By GuruFocus Research 03-08-2024